APOB and cardiovascular disorder: The increased level of APOB in the serum of e3 or e4 carriers is well established,[7, 21] and a high level of APOB is a validated biomarker of cardiovascular disease risk.[22] Lower levels of APOB in carriers of e2e2 and e2e3 genotypes compared to carriers of e3e3 are also established,[23] although the mechanism of action remains unclear.[24] The decreased levels of APOB we observed in e2 carriers may result from reduced production of very low density lipoprotein VLDL and increased clearance of remnant particles.